XIO Group will buy Israeli medical laser player Lumenis for about $510 million in cash. That price tag isn't much of a premium to the company's valuation because a rumor that it would be acquired for about $500 million by China's Fosun Pharma already pushed shares up earlier this year.
Medtronic has invested in a subsidiary of Arsenal Medical, a startup focused on developing a polymer-based foam to control intra-abdominal bleeding. The device giant gains an option to acquire the subsidiary, Arsenal AAA, upon the achievement of undisclosed milestones. Medtronic also didn't reveal how much it invested in the deal.
Swedish drug developer Recipharm bought a local CRO for 15.1 million kronor ($6.2 million), fleshing out its chemistry services as it works to expand its share of the European market.
Last month, reports said Valeant was eyeing up one of Egypt's largest drugmakers. Now, word has it, those talks have progressed, and the Canadian pharma could be ready to pull the trigger in the coming weeks.
Medical products company Hill-Rom is using its $2 billion acquisition of patient monitoring and diagnostics player Welch Allyn to decrease its reliance on sales of large, acute-care capital equipment--which are highly subject to pressure from macroeconomic changes.
Actavis may have changed its name to Allergan this week, but nothing has changed about its penchant for dealmaking. The newly bulked-up pharma struck again Wednesday, inking a pact for Kythera Biopharmaceuticals.
The freshly rebranded Allergan is planning to spend $2.1 billion on Kythera, maker of an injection to reduce chin fat, in a deal designed to bolster the company's strength in aesthetics.
Mylan can breathe a little easier knowing it has support from its largest shareholder in its quest to pick up Perrigo. After all, it's not just a big buyout at stake--but the opportunity to thwart its own unwanted takeover by generics rival Teva.
Respiratory biotech Pulmatrix has completed its nontraditional path to the public markets, closing a merger with upstart Ruthigen to inherit a Nasdaq listing, at the same time banking $10 million and partnering up with generics giant Mylan.
In their last letter to Mylan Chairman Robert Coury, Teva's leaders made it explicitly clear: They're proceeding down their takeover path whether Mylan likes it or not. And they took another step forward this week, further hiking Teva's stake in their target.